Breast

Article	Citations
Current and future burden of breast cancer: Global statistics for 2020 and 2040	1062
Global guidelines for breast cancer screening: A systematic review	102
Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer	91
Factors influencing five-year adherence to adjuvant endocrine therapy in breast cancer patients: A systematic review	73
Mammographic breast density and the risk of breast cancer: A systematic review and meta-analysis	70
Global challenges in breast cancer detection and treatment	64
Epidemiology of male breast cancer	59
Dissecting the biological heterogeneity of HER2-positive breast cancer	55
The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: A qualitative systematic review and thematic synthesis	51
The impact of young age at diagnosis (age <40 years) on prognosis varies by breast cancer subtype: A U.S. SEER database analysis	47
Effects of the COVID-19 pandemic on breast cancer screening in Taiwan	43
Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer	42
Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer	41
Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data fr	39
Occult breast cancer: Where are we at?	38
Breast cancer surgery with augmented reality	38
Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy	36
Tailored axillary surgery in patients with clinically node-positive breast cancer: Pre-planned feasibility substudy of TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)	36
A systematic review and meta-analysis on the effect of neoadjuvant chemotherapy on complications following immediate breast reconstruction	36
“The emerging role of capivasertib in breast cancer”	34
Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D	34
Feasibility and reliability of sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patients with positive axillary nodes at initial diagnosis: An up-to-date meta-analysis of 3,5	32
Clinical utility of the 21-gene assay in predicting response to neoadjuvant endocrine therapy in breast cancer: A systematic review and meta-analysis	32
Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis	31
The applicability of Magseed® for targeted axillary dissection in breast cancer patients treated with neoadjuvant chemotherapy	31

Targeting ADCC: A different approach to HER2 breast cancer in the immunotherapy era	31
Clinicopathological characteristics and prognosis of breast cancer with special histological types: A surveillance, epidemiology, and end results database analysis	30
Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer	29
De-escalating axillary surgery in early-stage breast cancer	29
Combined breast conservation therapy versus mastectomy for BRCA mutation carriers – A systematic review and meta-analysis	29
A systematic review of the impact of the COVID-19 pandemic on breast cancer screening and diagnosis	28
A multidisciplinary view of mastectomy and breast reconstruction: Understanding the challenges	28
Clinical recommendations for diagnosis and treatment according to current updated knowledge on BIA-ALCL	28
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study	27
Contralateral prophylactic mastectomy: A narrative review of the evidence and acceptability	27
Patient-reported outcomes one year after positive sentinel lymph node biopsy with or without axillary lymph node dissection in the randomized SENOMAC trial	26
Psychoeducation for breast cancer: A systematic review and meta-analysis	26
Locoregional therapy in de novo metastatic breast cancer: Systemic review and meta-analysis	26
Breast-related and body-related quality of life following autologous breast reconstruction is superior to implant-based breast reconstruction - A long-term follow-up study	25
Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy	24
Differences in sensitivity to neoadjuvant chemotherapy among invasive lobular and ductal carcinoma of the breast and implications on surgery–A systematic review and meta-analysis	24
Clinicopathological response to neoadjuvant therapies and pathological complete response as a biomarker of survival in human epidermal growth factor receptor-2 enriched breast cancer – A retrospective	23
Polygenic risk scores and breast cancer risk prediction	23
Hypofractionated versus conventional fractionated radiotherapy for breast cancer in patients with reconstructed breast: Toxicity analysis	23
Long-term health-related quality of life of breast cancer survivors remains impaired compared to the age-matched general population especially in young women. Results from the prospective controlled B	23
Positive effects of the enhanced recovery after surgery (ERAS) protocol in DIEP flap breast reconstruction	22
Effect of pathologic stages on postmastectomy radiation therapy in breast cancer receiving neoadjuvant chemotherapy and total mastectomy: A Cancer Database Analysis	22
Machine learning to predict individual patient-reported outcomes at 2-year follow-up for women undergoing cancer-related mastectomy and breast reconstruction (INSPiRED-001)	22
Unique challenges and outcomes of young women with breast cancers from a tertiary care cancer centre in India	21
Potential immune response to breast implants after immunization with COVID-19 vaccines	21
Locally advanced breast cancer	21
Tired of feeling tired – The role of circulating inflammatory biomarkers and long-term cancer related fatigue in breast cancer survivors	21
Preoperative non-palpable breast lesion localization, innovative techniques and clinical outcomes in surgical practice: A systematic review and meta-analysis	21
Optimal localization strategies for non-palpable breast cancers –A network meta-analysis of randomized controlled trials	21
Adverse health effects after breast cancer up to 14 years after diagnosis	21
Calorie restriction and synbiotics effect on quality of life and edema reduction in breast cancer-related lymphedema, a clinical trial	21
Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer	21
Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer	21
Pathologic response and residual tumor cellularity after neo-adjuvant chemotherapy predict prognosis in breast cancer patients	21
Why is appropriate healthcare inaccessible for many European breast cancer patients? – The EBCC 12 manifesto	20
Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer	20
Should oncoplastic breast conserving surgery be used for the treatment of early stage breast cancer? Using the GRADE approach for development of clinical recommendations	20
Impact of body mass index on overall survival in patients with metastatic breast cancer	20
Survival patterns of invasive lobular and invasive ductal breast cancer in a large population-based cohort with two decades of follow up	20
Omission of axillary sentinel lymph node biopsy in early invasive breast cancer	20
Safety of cyclin-dependent kinase4/6 inhibitor combined with palliative radiotherapy in patients with metastatic breast cancer	20
“This house believes that: Sentinel node biopsy alone is better than TAD after NACT for cN+ patients”	19
Aromatase inhibitors use and risk for cardiovascular disease in breast cancer patients: A population-based cohort study	19
Interstitial lung disease in patients treated with Cyclin-Dependent Kinase 4/6 inhibitors: A systematic review and meta-analysis of randomized controlled trials	19
Moderately hypofractionated post-operative radiation therapy for breast cancer: Systematic review and meta-analysis of randomized clinical trials	19
Optimized tumour infiltrating lymphocyte assessment for triple negative breast cancer prognostics	19
The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: A quantitative systematic review	19
Breast cancer screening using synthesized two-dimensional mammography: A systematic review and meta-analysis	18
Unresected screen-detected ductal carcinoma in situ: Outcomes of 311 women in the Forget-Me-Not 2 study	18
Efficacy and safety of palbociclib in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer with preexisting conditions: A post hoc analysis	18

Anticancer effects of radiation therapy combined with Polo-Like Kinase 4 (PLK4) inhibitor CFI-400945 in triple negative breast cancer	18
Immediate Breast Reconstruction after mastectomy with polyurethane implants versus textured implants: A retrospective study with focus on capsular contracture	18
Population-based mammography screening attendance in Sweden 2017–2018: A cross-sectional register study to assess the impact of sociodemographic factors	18
Impact of radiation dose on complications among women with breast cancer who underwent breast reconstruction and post-mastectomy radiotherapy: A multi-institutional validation study	18
Breast-conserving surgery with or without irradiation in women with invasive ductal carcinoma of the breast receiving preoperative systemic therapy: A cohort study	18
How I treat HER2-low advanced breast cancer	18
Low neighborhood socioeconomic status is associated with higher mortality and increased surgery utilization among metastatic breast cancer patients	18
First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study	17
The role of CDK4/6 inhibitors in early breast cancer	17
A prospective cohort study of the safety of breast cancer surgery during COVID-19 pandemic in the West of Scotland	17
Effects of physical exercise on cognitive function of breast cancer survivors receiving chemotherapy: A systematic review of randomized controlled trials	17
Axillary surgery in node-positive breast cancer	17
Moment of truth-adding carboplatin to neoadjuvant/adjuvant chemotherapy in triple negative breast cancer improves overall survival: An individual participant data and trial-level Meta-analysis	16
Progression-free survival and quality of life in metastatic breast cancer: The patient perspective	16
Clinical characteristics and survival outcome of patients with estrogen receptor low positive breast cancer	16
Symptoms in long-term breast cancer survivors: A cross-sectional study in primary care	16
Survival outcomes after breast-conserving therapy compared with mastectomy for patients with early-stage metaplastic breast cancer: a population-based study of 2412 patients	16
Is breast conservation superior to mastectomy in early stage triple negative breast cancer?	16
Predictive and prognostic values of tumor infiltrating lymphocytes in breast cancers treated with neoadjuvant chemotherapy: A meta-analysis	16
Can supplementary contrast-enhanced MRI of the breast avoid needle biopsies in suspicious microcalcifications seen on mammography? A systematic review and meta-analysis	16
Pathology after neoadjuvant treatment – How to assess residual disease	16
Palbociclib in combination with aromatase inhibitors in patients ≥ 75 years with oestrogen receptor-positive, human epidermal growth factor receptor 2 negative advanced breast cancer: A real-world mul	16
A multidisciplinary approach to optimizing care of patients treated with alpelisib	16
On top of that all, now Covid-19, too. A scoping review of specificities and correlates of fear of cancer recurrence in breast cancer patients during COVID-19	15
SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors	15
Is sarcopenia a missed factor in the management of patients with metastatic breast cancer?	15
Pregnancy associated breast cancer (PABC): Report from a gestational cancer registry from a tertiary cancer care centre, India	15
NT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patients	15
Phyllodes tumors of the breast: Adjuvant radiation therapy revisited	15
Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A cost-effectiveness analysis	15
Neoadjuvant chemotherapy and HER2 dual blockade including biosimilar trastuzumab (SB3) for HER2-positive early breast cancer: Population based real world data from the Danish Breast Cancer Group (DBCG	15
Are English-language online patient education materials related to breast cancer risk assessment understandable, readable, and actionable?	15
The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: Novel prognostic indexes based on ctDNA	14
Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastati	14
Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer	14
Acute toxicity and health-related quality of life after accelerated whole breast irradiation in 5 fractions with simultaneous integrated boost	14
COVID-19 vaccination in patients with breast cancer and gynecological malignancies: A German perspective	14
A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting	14
Mammographic density and prognosis in primary breast cancer patients	14
Mammographic sensitivity as a function of tumor size: A novel estimation based on population-based screening data	14
Safety and efficacy of cyclin-dependent kinase inhibitor rechallenge following ribociclib-induced limiting hypertransaminasemia	13
Selection of neoadjuvant treatment based on the 21-GENE test results in luminal breast cancer	13
Differences in breast cancer risk after benign breast disease by type of screening diagnosis	13
Automated coronary artery calcium scoring in patients with breast cancer to assess the risk of heart disease following adjuvant radiation therapy	13
Uptake of bilateral-risk-reducing-mastectomy: Prospective analysis of 7195 women at high-risk of breast cancer	13
A scoping review of interactive and personalized web-based clinical tools to support treatment decision making in breast cancer	13
Statin use and patterns of breast cancer recurrence in the Malmö Diet and Cancer Study	13
Real-world comparative effectiveness of palbociclib plus letrozole versus letrozole in older patients with metastatic breast cancer	13
Immediate direct-to-implant breast reconstruction with acellular dermal matrix: Evaluation of complications and safety	13
Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer	13
CDK 4/6 inhibitors mired in uncertainty in HR positive and HER2 negative early breast cancer	13
Anthracyclines in the treatment of early breast cancer friend or foe?	12
Residual breast tissue after robot-assisted nipple sparing mastectomy	12
Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib	12
Decisional conflict in breast cancer patients considering immediate breast reconstruction	12
Tumour-infiltrating lymphocytes in non-invasive breast cancer: A systematic review and meta-analysis	12
Quality indicators for breast cancer care: A systematic review	12
Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: Subgroup analysis of the p	12
The underused potential of breast conserving therapy after neoadjuvant system treatment – Causes and solutions	12
Rising incidence of late stage breast cancer after COVID-19 outbreak. Real-world data from the Italian COVID-DELAY study	12
Evidence-based tailored nutrition educational intervention improves adherence to dietary guidelines, anthropometric measures and serum metabolic biomarkers in early-stage breast cancer patients: A pro	12
The emerging role of real-world data in advanced breast cancer therapy: Recommendations for collaborative decision-making	12
Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterations	12
Addressing disparities and challenges in underserved patient populations with metastatic breast cancer in Europe	11
Retrospective study of malignant phyllodes tumors of the breast: Younger age, prior fibroadenoma surgery, malignant heterologous elements and surgical margins may predict recurrence	11
The effect of family history on screening procedures and prognosis in breast cancer patients - Results of a large population-based case-control study	11
Cost-effectiveness of abbreviated-protocol MRI screening for women with mammographically dense breasts in a national breast cancer screening program	11
Rates of margin positive resection with breast conservation for invasive breast cancer using the NCDB	11
Prevalence, trend and disparities of palliative care utilization among hospitalized metastatic breast cancer patients who received critical care therapies	11
Which clinical, radiological, histological, and molecular parameters are associated with the absence of enhancement of known breast cancers with Contrast Enhanced Digital Mammography (CEDM)?	11
A pilot study evaluating the effect of early physical therapy on pain and disabilities after breast cancer surgery: Prospective randomized control trail	11
Individualized-thresholding Shear Wave Elastography combined with clinical factors improves specificity in discriminating breast masses	11
Views of healthcare professionals about the role of active monitoring in the management of ductal carcinoma in situ (DCIS): Qualitative interview study	11
Effects of tamoxifen and aromatase inhibitors on the risk of acute coronary syndrome in elderly breast cancer patients: An analysis of nationwide data	11
Giving meaning to patient reported outcomes in breast reconstruction after mastectomy – A systematic review of available scores and suggestions for further research	11
Barrier films for the prevention of acute radiation dermatitis in breast cancer: A systematic review and meta-analysis of randomised controlled trials	11
Development of a novel nomogram-based online tool to predict axillary status after neoadjuvant chemotherapy in cN+ breast cancer: A multicentre study on 1,950 patients	11
Concordance of HER2-low scoring in breast carcinoma among expert pathologists in the United Kingdom and the republic of Ireland –on behalf of the UK national coordinating committee for breast patholog	11
Association of molecular subtype concordance and survival outcome in synchronous and metachronous bilateral breast cancer	11
Tailored axillary surgery – A novel concept for clinically node positive breast cancer	11

Is the skin microbiota a modifiable risk factor for breast disease?: A systematic review	11
Deep learning with biopsy whole slide images for pretreatment prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer：A multicenter study	11
The impact of standardized structured reporting of pathology reports for breast cancer care	10
Towards population-based genetic screenings for breast and ovarian cancer: A comprehensive review from economic evaluations to patient perspectives	10
Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer	10
Epidemiological features of primary breast lymphoma patients and development of a nomogram to predict survival	10
Unleashing NK- and CD8 T cells by combining monalizumab and trastuzumab for metastatic HER2-positive breast cancer: Results of the MIMOSA trial	10
Tamoxifen related side effects and their impact on breast cancer incidence: A retrospective analysis of the randomised IBIS-I trial	10
Acinic cell carcinoma of the breast: A comprehensive review	10
Eligibility of real-world patients with metastatic breast cancer for clinical trials	10
Ovarian reserve of women with and without BRCA pathogenic variants: A systematic review and meta-analysis	10
Trends in incidence, treatment, survival and subsequent breast cancer in lobular carcinoma in situ in the Netherlands: A population-based analysis	10
Impact of molecular subtype on 1325 early-stage breast cancer patients homogeneously treated with hypofractionated radiotherapy without boost: Should the indications for radiotherapy be more personali	10
Does mainstream BRCA testing affect surgical decision-making in newly-diagnosed breast cancer patients?	10
A nested case-control study on radiation dose-response for cardiac events in breast cancer patients in Germany	10
Breast magnetic resonance imaging as a problem solving tool in women recalled at biennial screening mammography: A population-based study in the Netherlands	10
Efficacy of neoadjuvant treatment with or without pertuzumab in patients with stage II and III HER2-positive breast cancer: a nationwide cohort analysis of pathologic response and 5-year survival	9
Efficacy and safety of PARP inhibitors in patients with BRCA-mutated advanced breast cancer: A meta-analysis and systematic review	9
Cost-effectiveness of postmastectomy hypofractionated radiation therapy vs conventional fractionated radiation therapy for high-risk breast cancer	9
Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: A multicenter study	9
Hypofractionation with simultaneous integrated boost after breast-conserving surgery: Long term results of two phase-II trials	9
Evolution of physical activity and body weight changes in breast cancer survivors five years after diagnosis – VICAN 2 & 5 French national surveys	9
Effect of a health literacy training program for surgical oncologists and specialized nurses on disparities in referral to breast cancer genetic testing	9
First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study	9
Trastuzumab emtansine for HER2-positive metastatic breast cancer: Outcomes from a whole-of-population Australian cohort	9
Treatment of adenoid cystic carcinoma of the breast: Is postoperative radiation getting its due credit?	9
Trajectories of cognitive performance over five years in a prospective cohort of patients with breast cancer (NEON-BC)	9
Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer	9
Incidence, risk factors and survival of patients with brain metastases at initial metastatic breast cancer diagnosis in China	9
Development of novel agents for the treatment of early estrogen receptor positive breast cancer	9
Experiences, expectations and preferences regarding MRI and mammography as breast cancer screening tools in women at familial risk	9
Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year single institutional experience	9
Randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer	9
Cost-utility of talazoparib monotherapy treatment for locally advanced or metastatic breast cancer in Spain	8
Risk of ipsilateral breast tumor recurrence and contralateral breast cancer in patients with and without TP53 variant in a large series of breast cancer patients	8
Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer	8
Chemotherapy and 21-gene recurrence score testing for older breast cancer patients: A competing-risks analysis	8
The first reported case of trastuzumab induced interstitial lung disease associated with anti-neutrophil cytoplasmic antibody vasculitis – A case report and a prospective cohort study on the usefulnes	8
Frequency and outcomes of benign breast biopsies in trans women: A nationwide cohort study	8
Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases	8
Essential amino acids deprivation is a potential strategy for breast cancer treatment	8
Mammographic density and interval cancers in mammographic screening: Moving towards more personalized screening	8
Older women’s experience with breast cancer treatment: A systematic review of qualitative literature	8
Effects of postmastectomy radiotherapy on survival in different age groups for patients with T3N0M0 breast cancer	8
Presentation and survival by hormonal receptor status in metaplastic breast cancer: A propensity score-matched analysis	8
Survival of south african women with breast cancer receiving anti-retroviral therapy for HIV	8
Trends in axillary surgery and clinical outcomes among breast cancer patients with sentinel node metastasis	8
Real-world effectiveness of palbociclib plus fulvestrant in advanced breast cancer: Results from a population-based cohort study	8
Patterns of care of breast cancer patients in Morocco – A study of variations in patient profile, tumour characteristics and standard of care over a decade	8
Information needs on breast cancer genetic and non-genetic risk factors in relatives of women with a BRCA1/2 or PALB2 pathogenic variant	8
Axillary lymph node dissection: Dead or still alive?	8
Adjuvant CDK4/6 inhibitors combined with endocrine therapy in HR-positive, HER2-negative early breast cancer: A meta-analysis of randomized clinical trials	8
Antibody-drug conjugates targeting Trop-2: Clinical developments in early breast cancer therapy	8
Sometimes it is better to just make it simple. De-escalation of oncoplastic and reconstructive procedures	8
Immune checkpoint inhibition in the treatment of early stage triple negative breast cancer: 2021 update	8
Internal mammary node irradiation in node-positive breast cancer treated with mastectomy and taxane-based chemotherapy	8
Imaging of lumpectomy surface with large field-of-view confocal laser scanning microscope for intraoperative margin assessment - POLARHIS study	8
HER2 positivity is not associated with adverse prognosis in high-risk estrogen receptor-positive early breast cancer patients treated with chemotherapy and trastuzumab	8
Prospective cohort study of febrile neutropenia in breast cancer patients administered with neoadjuvant and adjuvant chemotherapies: CSPOR-BC FN study	8
Breast cancer survival in Brazil: How much health care access impact on cancer outcomes?	8
Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer	7
BRCA1/2 testing for genetic susceptibility to cancer after 25 years: A scoping review and a primer on ethical implications	7
Systemic treatment with or without ablative therapies in oligometastatic breast cancer: A single institution analysis of patient outcomes	7
A novel algorithm to reduce VTE in peri-operative patients on tamoxifen	7
Prediction of severe neutropenia and diarrhoea in breast cancer patients treated with abemaciclib	7
Evaluation of physician performance using a concurrent-read artificial intelligence system to support breast ultrasound interpretation	7
Breast cancer, breast cancer-directed radiation therapy and risk of hypothyroidism: A systematic review and meta-analysis	7
Loco-regional adjuvant radiation therapy in breast cancer patients with positive axillary lymph-nodes at diagnosis (CN2) undergoing preoperative chemotherapy and with complete pathological lymph-nodes	7
SABR in oligometastatic breast cancer: Current status and future directions	7
Local treatment options for young women with ductal carcinoma in situ: A systematic review and meta-analysis comparing breast conserving surgery with or without adjuvant radiotherapy, and mastectomy	7
Effects of supervised exercise during adjuvant endocrine therapy in overweight or obese patients with breast cancer: The I-MOVE study	7
Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP)	7
Real-world data of HER2-low metastatic breast cancer: A population based cohort study	7
Real-world treatment patterns of subsequent therapy after palbociclib in patients with advanced breast cancer in Japan	7
Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer: Regulatory aspects and clinical impact in Europe	7
Real de-escalation or escalation in disguise?	7
The usefulness of CanAssist breast in the assessment of recurrence risk in patients of ethnic Indian origin	7
Higher-risk breast cancer in women aged 80 and older: Exploring the effect of treatment on survival	7
Clinical predictors of cardiac toxicity in HER2-positive early breast cancer patients treated with adjuvant s.c. versus i.v. trastuzumab	7
Obstetric complications at time of delivery amongst breast cancer survivors: A population-based cohort study	7
Customizing early breast cancer therapies – The 2021 St. Gallen International Breast Cancer Consensus Conference	7
Does neoadjuvant chemotherapy regimen affect sarcopenia status in patients with breast cancer?	7
Cost-effectiveness of trastuzumab biosimilar combination therapy and drug wastage as first-line treatment for HER2-positive metastatic breast cancer	6
Tissue- and liquid biopsy-based biomarkers for immunotherapy in breast cancer	6
Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic	6
Is weight-based IV dosing of trastuzumab preferable to SC fixed-dose in some patients? A systematic scoping review	6
A retrospective validation of CanAssist Breast in European early-stage breast cancer patient cohort	6
A systematic review and meta-analysis of BRCA1/2 mutation for predicting the effect of platinum-based chemotherapy in triple-negative breast cancer	6
Digital analysis of distant and cancer-associated mammary adipocytes	6
Diagnosis, biology and epidemiology of oligometastatic breast cancer	6
Family history of breast cancer, mammographic breast density and breast cancer risk: Findings from a cohort study of Korean women	6
The role of the radiation therapy breast boost in the 2020s	6
Adjuvant chemotherapy could benefit early-stage ER/PR positive mucinous breast cancer: A SEER-based analysis	6
Efficacy of CT-P6 (trastuzumab biosimilar) versus reference trastuzumab in combination with pertuzumab in HER2-positive early-stage breast cancer: Preclinical and real-life clinical data	6
The efficacy and safety of paclitaxel plus bevacizumab therapy in breast cancer patients with visceral crisis	6